

## Substance Use Disorder Screening Guide for Primary Care Physicians

### Purpose of Screening

Substance use exists on a spectrum from non-use to risky use to substance use disorder (SUD). A validated screen identifies risk early; it does **not** establish a diagnosis. Primary care clinicians can prevent harm by screening routinely, responding without judgment, and matching intervention intensity to clinical risk.

**1 in 10**

Nevada adolescents ages 12-17 met criteria for a past-year SUD (10.05%).<sup>[1]</sup>

**< 2 min**

S2BI and BSTAD can be self- or clinician-administered in busy primary care settings.<sup>[3]</sup>

**SCREEN**

Use a validated tool at health supervision visits and appropriate acute visits.<sup>[2]</sup>

### When and How to Screen

- Screen annually at well visits - and whenever mood, school, sleep, injury, or behavior raises concern.
- Screen privately with a validated tool; explain confidentiality and its limits.
- A negative screen does not replace clinical judgment; reassess when concerns persist.

**Neutral opening:** *'I ask every patient about substance use because it can affect health.'*

### Validated Screening Tools

| Tool                        | Age   | Time    | Format / focus                                                                                                                           | Key interpretation                                                                                                                                                      |
|-----------------------------|-------|---------|------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <a href="#">S2BI</a>        | 12-17 | <2 min  | Self- or clinician-administered. Past-year frequency across tobacco, alcohol, cannabis, prescription medication misuse, and other drugs. | Triages into no reported use, lower risk, or higher risk. Frequency guides brief intervention and follow-up. <sup>[3]</sup>                                             |
| <a href="#">BSTAD</a>       | 12-17 | <2 min  | Self- or clinician-administered. Reports number of past-year use days for common substances, then asks about additional substances.      | Returns a substance-specific risk level and suggested clinical actions. <sup>[3]</sup>                                                                                  |
| <a href="#">CRAFT 2.1+N</a> | 12-21 | Few min | Self-administered or interview. Screens alcohol/drugs, riding/driving risk, and nicotine dependence (+N).                                | Part B: 2 or more YES responses suggests a serious problem requiring further assessment. Any +N <sup>[4]</sup> dependence item also warrants assessment. <sup>[4]</sup> |

**Practice pearl:** Self-administered screening may improve privacy, efficiency, and disclosure. Review results confidentially.

## Responding to a Positive Screen

### Immediate Safety First

Call 911 / send to the emergency department for suspected overdose, severe intoxication or withdrawal, difficulty awakening, slowed or stopped breathing, seizure, or other acute medical instability. Activate emergency psychiatric services for imminent suicide or violence risk.

## Five-Step Clinical Response

| Step                               | What to do                                                                                                                                                                                                           |
|------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. Thank and normalize             | Acknowledge honesty. Use person-first, non-stigmatizing language. Ask permission to discuss the result.                                                                                                              |
| 2. Clarify the pattern             | Substance, route, amount/potency, frequency, context, source, last use, co-use, cravings, loss of control, attempts to cut down, and consequences.                                                                   |
| 3. Assess safety                   | Overdose history; driving/riding; use alone; mixing substances; counterfeit pills; withdrawal; injuries; access to medications/firearms; pregnancy and sexual health risks when relevant.                            |
| 4. Assess function and comorbidity | School, family, peers, sleep, legal issues, trauma, depression, anxiety, ADHD, eating disorders, psychosis, and suicide risk. Examine and order tests based on presentation rather than as a substitute for history. |
| 5. Match action to risk            | Deliver a brief intervention, involve family when safe and appropriate, arrange follow-up, and refer or treat according to severity and level-of-care needs.                                                         |

## Risk-Level Action

| Screen / pattern     | Clinical meaning                                                                                          | Primary care action                                                                                                                                                                            |
|----------------------|-----------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| No reported use      | No current use disclosed                                                                                  | Reinforce strengths and non-use; provide anticipatory guidance; re-screen routinely.                                                                                                           |
| Any use / lower risk | Experimentation or occasional use without current impairment                                              | Brief intervention using motivational interviewing; clear recommendation not to use; driving/overdose counseling; close follow-up.                                                             |
| Higher risk          | Frequent use, CRAFFT concern, high-risk context, or emerging consequences                                 | Complete diagnostic assessment; engage family when appropriate; treat co-occurring conditions; refer for evidence-based care; schedule prompt follow-up.                                       |
| Likely SUD / OUD     | Impaired control, functional impairment, hazardous use, tolerance/withdrawal, or ongoing use despite harm | Determine level of care using a multidimensional assessment; coordinate specialty treatment. For OUD, offer or rapidly connect to medication treatment and provide naloxone. <sup>[5][6]</sup> |

### Brief Intervention: Use the CRAFFT 5 R's

**Review** results; **Recommend** non-use; counsel about **Riding/Driving**; elicit the patient's **Response** and reasons for change; **Reinforce** self-efficacy. <sup>[4]</sup>

## Treatment and Clinical Pearls

### Evidence-Based Treatment

Match treatment to severity, developmental needs, family context, and co-occurring conditions. Recurrence of use should prompt reassessment - not judgment.

| Intervention                     | Primary care application                                                         |
|----------------------------------|----------------------------------------------------------------------------------|
| <b>Family-based therapy</b>      | Engage caregivers and the home environment when safe and clinically appropriate. |
| <b>Motivational interviewing</b> | Explore ambivalence and strengthen the patient's own reasons for change.         |
| <b>CBT</b>                       | Build coping skills, identify triggers, and change patterns that maintain use.   |
| <b>Contingency management</b>    | Reinforce treatment participation and recovery behaviors.                        |
| <b>Integrated care</b>           | Treat SUD and co-occurring conditions together; coordinate needed supports.      |

### Medication Considerations

| Condition                   | Clinical note                                                                                                                               |
|-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Opioid use disorder</b>  | Offer or rapidly connect to buprenorphine treatment; therapy is an additional support, not a prerequisite. Provide naloxone. <sup>[5]</sup> |
| <b>Nicotine dependence</b>  | Pair behavioral treatment with developmentally appropriate cessation support; individualize medication decisions.                           |
| <b>Alcohol use disorder</b> | Use behavioral and family treatment; consider medication with specialist or NV PAL consultation.                                            |

### Substance-Specific Clinical Pearls

| Substance                          | Assess and counsel                                                                                             |
|------------------------------------|----------------------------------------------------------------------------------------------------------------|
| <b>Cannabis</b>                    | Ask about potency and route; assess cognition, anxiety/paranoia, psychosis risk, school function, and driving. |
| <b>Alcohol</b>                     | Assess binge use, blackouts, injuries, co-ingestants, driving, and withdrawal history.                         |
| <b>Nicotine / vaping</b>           | Ask what is vaped, frequency, cravings/withdrawal, quit attempts, and respiratory symptoms.                    |
| <b>Opioids / counterfeit pills</b> | Assess overdose, use alone, co-use, route, and naloxone access. <sup>[5][7]</sup>                              |

## Safety, Follow-Up, and Resources

### Reduce Immediate Harm

#### USE

Avoid using alone, mixing substances, and impaired driving.

#### OVERDOSE

Carry naloxone; assume non-pharmacy pills may contain fentanyl. Suspected overdose: give naloxone, call 911, and begin rescue breathing/CPR.

#### AT HOME

Lock alcohol, cannabis, medications, and firearms; dispose of unused medication.

### Follow-Up and Resources

**Follow up:** Reassess use, cravings, safety, function, and co-occurring symptoms. Coordinate care and adjust the level of care as needed.

- **Consult:** [NV PAL](#)
- **Find treatment:** [SAMHSA](#)
- **Crisis:** [988](#)
- **(702) 553-4528** Monday-Friday, 9:00 AM-5:00 PM PST [Text to consult](#)

**Selected sources:** [\[1\] SAMHSA Nevada estimates](#) [\[2\] AAP SBIRT](#) [\[3\] NIDA screening tools](#) [\[4\] CRAFT guidance](#) [\[5\] AAP opioid guidance](#) [\[6\] ASAM Criteria](#) [\[7\] DEA One Pill Can Kill](#)



[nvpal.org](https://nvpal.org)

*A grant funded program of:*